tisotumab vedotin + pembrolizumab

**Tisotumab vedotin + pembrolizumab** is a combination regimen composed of two distinct drugs used primarily in clinical investigation for advanced cervical and vaginal cancers. Tisotumab vedotin is an antibody-drug conjugate targeting tissue factor (TF) on tumor cells, delivering a cytotoxic payload (monomethyl auristatin E) to induce cell cycle arrest and apoptosis in TF-expressing cells. Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by blocking programmed death-1 (PD-1), restoring T-cell mediated antitumor immunity. The combination is being studied for potential synergistic effects, with preclinical data suggesting that antibody-drug conjugates may enhance tumor immunogenicity and dendritic cell maturation, potentially boosting the response to immune checkpoint inhibition. This regimen is being evaluated in ongoing phase Ib/II (e.g., innovaTV 205) clinical trials for relapsed or metastatic cervical cancer and explored in rare gynecologic cancers such as vaginal cancer[1][3][5][6].